Your browser doesn't support javascript.
loading
Lymphovascular Invasion is an Independent Negative Prognostic Factor in Esophageal Adenocarcinoma.
Donato, Britton B; Campany, Megan E; Brady, Justin T; Asher Jenkins, J; Butterfield, Richard; Armstrong, Valerie; Beamer, Staci E; Dos Santos, Pedro Reck; D'Cunha, Jonathan.
Affiliation
  • Donato BB; Department of Cardiothoracic Surgery, Mayo Clinic, Phoenix, AZ, USA. bdonato@mcw.edu.
  • Campany ME; Division of Cardiothoracic Surgery, Medical College of Wisconsin, Milwaukee, WI, USA. bdonato@mcw.edu.
  • Brady JT; Mayo Clinic Alix School of Medicine, Mayo Clinic, Scottsdale, AZ, USA.
  • Asher Jenkins J; Department of Surgery, Mayo Clinic, Phoenix, AZ, USA.
  • Butterfield R; Department of Cardiothoracic Surgery, Mayo Clinic, Phoenix, AZ, USA.
  • Armstrong V; Department of Surgery, Mayo Clinic, Phoenix, AZ, USA.
  • Beamer SE; Department of Quantitative Health Sciences, Mayo Clinic, Phoenix, AZ, USA.
  • Dos Santos PR; Department of Surgery, Mayo Clinic, Phoenix, AZ, USA.
  • D'Cunha J; Department of Cardiothoracic Surgery, Mayo Clinic, Phoenix, AZ, USA.
Ann Surg Oncol ; 2024 Jul 17.
Article in En | MEDLINE | ID: mdl-39017972
ABSTRACT

BACKGROUND:

The significance of lymphovascular invasion (LVI) in esophageal adenocarcinoma (EAC) has not yet been described. Potential utility as an adjunct to current staging guidelines remains unknown.

METHODS:

The National Cancer Database was queried from 2006 to 2020. Univariate and multivariable models, Kaplan Meier method, and log-rank test were used. Subgroup analyses by pN stage were conducted.

RESULTS:

Of 9,689 patients, 23.2% had LVI. LVI was an independent prognostic factor (hazard ratio [HR] 1.401, 95% confidence interval [CI] 1.307-1.502, p < 0.0001) with reduction in median survival to 20.0 months (95% CI 18.9-21.4) from 39.7 months (95% CI 37.8-42.3, p < 0.0001). Multivariable survival analysis adjusted on pN and pT stage found that patients with LVI had decreased survival in a given pN stage (p < 0.001). pN0/LVI+ patients had a similar prognosis to the higher staged pN1/LVI- (28.6 months), although pN1/LVI- patients did slightly worse (p = 0.0135). Additionally, patients with pN1/LVI+ had equivalent survival compared with pN2/LVI- (p = 0.178) as did pN2/LVI+ patients compared with pN3/LVI- (p = 0.995).

CONCLUSIONS:

In these data, LVI is an independent negative prognostic factor in EAC. LVI was associated with a survival reduction similar to an upstaged nodal status irrespective of T stage. Patients with LVI may be better classified at a higher pN stage.
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Ann Surg Oncol Journal subject: NEOPLASIAS Year: 2024 Document type: Article Affiliation country:

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Ann Surg Oncol Journal subject: NEOPLASIAS Year: 2024 Document type: Article Affiliation country: